Core Viewpoint - Humana's recent earnings report indicates a mixed performance with a significant adjusted loss per share, despite revenue growth driven by its CenterWell unit, raising questions about future performance and investor sentiment [2][3][21]. Financial Performance - Humana reported a Q4 2025 adjusted loss of $3.96 per share, which was narrower than the consensus estimate of a loss of $4.01 per share but wider than the prior year's loss of $2.16 per share [2]. - Adjusted revenues increased by 11.8% year over year to $32.6 billion, surpassing the consensus mark by 2.4% [2]. - Premiums totaled $30.9 billion, up 11.3% year over year, exceeding both the consensus estimate of $30.2 billion and the internal estimate of $29.8 billion [4]. - Total operating expenses rose by 12% year over year to $33.3 billion, higher than the internal estimate of $31.8 billion [5]. Segment Performance - The Insurance segment's adjusted revenues increased by 11.3% year over year to $31.3 billion, driven by improved per-member premiums and an expanding customer base [6]. - CenterWell recorded revenues of $6 billion, a 16.2% year-over-year increase, benefiting from higher revenues in pharmacy and primary care businesses [8]. Membership and Operating Metrics - Total medical membership in the Insurance segment fell by 8.2% year over year to 15 million, below the consensus estimate of 15.1 million [7]. - The benefit ratio for the quarter was 93%, deteriorating by 150 basis points year over year [5]. Cash Flow and Capital Deployment - Humana ended Q4 with cash and cash equivalents of $4.2 billion, an increase of 89.1% from the end of 2024 [10]. - The company generated net cash from operations of $921 million in 2025, a decline of 68.9% from the previous year [11]. - Humana repurchased shares worth $151 million and paid dividends of $430 million during 2025 [12]. Full-Year and Future Outlook - For 2025, adjusted revenues reached $129.8 billion, a 10.7% year-over-year growth, while adjusted EPS rose by 5.7% to $17.14 [13]. - For 2026, revenues are projected to be at least $160 billion, indicating a 23.4% increase from 2025, with adjusted EPS expected to decline by 47.5% to at least $9.00 [14][15]. - Management anticipates growth in Individual Medicare Advantage membership by around 25% in 2026 [15]. Market Position and Competitor Performance - Humana's stock has seen a downward trend in estimates since the earnings release, with a Zacks Rank of 3 (Hold), suggesting an in-line return in the near term [21]. - In comparison, Molina, a competitor in the same industry, reported a revenue increase of 8.3% year over year, but has a Zacks Rank of 5 (Strong Sell) due to negative estimate revisions [22][23].

分组1 - The Joint Corp. reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, with an earnings surprise of +33.33% [1] - The company achieved revenues of $15.17 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 10.59% and showing an increase from $14.45 million year-over-year [2] - The Joint has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] 分组2 - The stock has underperformed the market, losing about 2.4% since the beginning of the year compared to a 1% decline in the S&P 500 [3] - The current consensus EPS estimate for the coming quarter is $0.15 on $14 million in revenues, and for the current fiscal year, it is $0.57 on $55.41 million in revenues [7] - The Zacks Industry Rank for Medical - HMOs is currently in the bottom 9% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - Investors in Humana Inc. (HUM) should closely monitor the stock due to significant movements in the options market, particularly the Mar 20, 2026 $32.50 Call, which has shown high implied volatility [1] Group 1: Implied Volatility - Implied volatility indicates the market's expectations for future stock movement, with high levels suggesting potential significant price changes or upcoming events that could lead to a rally or sell-off [2] - Options traders often seek high implied volatility options to sell premium, aiming to benefit from the decay of options value if the stock does not move as much as anticipated [4] Group 2: Analyst Sentiment - Humana currently holds a Zacks Rank of 4 (Sell) within the Medical - HMOs Industry, placing it in the bottom 5% of the Zacks Industry Rank [3] - Over the past 60 days, two analysts have raised their earnings estimates for the current quarter, while five have lowered theirs, resulting in a decrease in the Zacks Consensus Estimate from $9.99 to $9.84 per share [3]

Core Viewpoint - The Zacks Equity Research team highlights recent performance and outlook for several companies, including UnitedHealth Group, Honeywell, Shopify, and Optex Systems, emphasizing their respective strengths and challenges in the current market environment [2][4][5][6][12]. UnitedHealth Group Inc. (UNH) - UnitedHealth's shares have declined by 3.9% over the past six months, slightly better than the Zacks Medical - HMOs industry's decline of 4.6% [4]. - The company faces rising medical costs, with a medical care ratio (MCR) projected at 89.1% for 2025, alongside elevated debt and interest expenses impacting financial flexibility [4]. - Despite the share price decline, UnitedHealth's fourth-quarter earnings exceeded estimates, supported by steady revenue growth from Optum and UnitedHealthcare, and strong cash flow with significant shareholder returns [5]. Honeywell International Inc. (HON) - Honeywell's shares have outperformed the Zacks Diversified Operations industry over the past six months, increasing by 18.6% compared to 1.4% for the industry [6]. - The company benefits from strong performance in commercial aviation and building automation, particularly in the Aerospace segment driven by defense business strength and growth in air transport flight hours [6]. - However, Honeywell faces challenges in its Industrial Automation segment due to lower demand, increasing operating costs, and significant balance sheet debt from acquisitions [8]. Shopify Inc. (SHOP) - Shopify's shares have underperformed the Zacks Internet - Services industry, declining by 12.7% compared to a 43.1% increase for the industry [9]. - The company is experiencing gross margin pressure due to higher hosting costs and a new paid trial program, which affects profitability [9]. - Despite these challenges, Shopify's expanding merchant base and investment in AI-driven tools are expected to enhance customer engagement and operational efficiency [10][11]. Optex Systems Holdings, Inc. (OPXS) - Optex Systems' shares have outperformed the Zacks Aerospace - Defense Equipment industry, increasing by 20.1% compared to 18.6% for the industry [12]. - The company reported a 31.7% year-over-year increase in Q1 FY26 orders, driven by strong demand for periscopes and optical assemblies, with quarterly revenues rising by 11.6% to $9.1 million [12][13]. - Recent multi-year contract awards exceeding $6 million provide revenue visibility into 2027, although gross margins have declined due to mix pressure and higher general and administrative costs [13].

分组1 - Select Medical reported quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share, and down from $0.18 per share a year ago, representing an earnings surprise of -31.57% [1] - The company posted revenues of $1.4 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.60%, and up from $1.31 billion year-over-year [2] - Select Medical has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained about 9.9% since the beginning of the year, compared to the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the coming quarter is $0.42 on revenues of $1.42 billion, and for the current fiscal year, it is $1.34 on revenues of $5.64 billion [7] - The Zacks Industry Rank for Medical - HMOs is currently in the bottom 9% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

Core Insights - Centene Corporation reported a quarterly loss of $1.19 per share, which was better than the estimated loss of $1.22 per share [1][3] - The company's revenue for the quarter ending December 2025 was $49.73 billion, exceeding the estimated $48.41 billion and representing a 21.9% increase from the previous year's $40.81 billion [2][6] - For the full year 2025, Centene reported a GAAP diluted loss per share of $13.53, while the adjusted diluted earnings per share were $2.08, with projections for adjusted diluted earnings per share to exceed $3.00 in 2026 [4][6] Financial Performance - Centene's EPS of -$1.19 was a positive surprise compared to the Zacks Consensus Estimate of a $1.25 loss, marking a 4.76% positive deviation [3] - The company has consistently exceeded consensus revenue estimates over the past four quarters, demonstrating strong performance [2] - The Health Benefits Ratio (HBR) for the fourth quarter of 2025 was 94.3%, indicating improvements in Medicaid HBR [4][6] Financial Metrics - Centene's price-to-earnings (P/E) ratio is -3.55, and the price-to-sales ratio is 0.10, reflecting its current negative earnings situation [5] - The debt-to-equity ratio stands at 0.84, suggesting a moderate level of debt compared to equity [5] - A current ratio of 1.08 indicates that Centene maintains a reasonable level of short-term financial health [5]

Core Insights - Centene reported a quarterly loss of $1.19 per share, which was better than the Zacks Consensus Estimate of a loss of $1.25, marking an earnings surprise of +4.76% [1] - The company generated revenues of $49.73 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 3.08% and showing a year-over-year increase from $40.81 billion [2] Financial Performance - Over the last four quarters, Centene has surpassed consensus EPS estimates three times and topped revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is $1.93 on revenues of $48 billion, and for the current fiscal year, it is $2.89 on revenues of $191.31 billion [7] Market Position - Centene shares have declined about 3% since the beginning of the year, while the S&P 500 has only declined by 0.7% [3] - The Zacks Industry Rank for Medical - HMOs, which includes Centene, is currently in the bottom 7% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8] Future Outlook - The company's earnings outlook will be crucial for determining the stock's immediate price movement, with management's commentary on the earnings call being particularly important [3][4] - The estimate revisions trend for Centene was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

分组1 - Cigna reported quarterly earnings of $8.08 per share, exceeding the Zacks Consensus Estimate of $7.87 per share, and up from $6.64 per share a year ago, representing an earnings surprise of +2.70% [1] - The company achieved revenues of $72.5 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.66%, compared to $65.68 billion in the same quarter last year [2] - Cigna has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market with a loss of about 1.3% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is $7.24 on revenues of $67.7 billion, and for the current fiscal year, it is $30.37 on revenues of $285.06 billion [7] - The Medical - HMOs industry, to which Cigna belongs, is currently ranked in the bottom 6% of over 250 Zacks industries, which may impact stock performance [8]

分组1 - UnitedHealth Group reported quarterly earnings of $2.11 per share, exceeding the Zacks Consensus Estimate of $2.09 per share, but down from $6.81 per share a year ago, representing an earnings surprise of +0.83% [1] - The company posted revenues of $113.22 billion for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.04%, and up from $100.81 billion year-over-year [2] - Over the last four quarters, UnitedHealth has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] 分组2 - The stock has gained approximately 6.5% since the beginning of the year, outperforming the S&P 500's gain of 1.5% [3] - The current consensus EPS estimate for the upcoming quarter is $6.36 on revenues of $113.89 billion, and for the current fiscal year, it is $17.61 on revenues of $457.6 billion [7] - The Zacks Industry Rank for Medical - HMOs is in the bottom 7% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - UnitedHealth Group's stock has shown resilience with a recent increase, but upcoming earnings are expected to reflect a significant decline in earnings per share year-over-year [1][2]. Financial Performance - UnitedHealth Group closed at $347.75, up 2.75% from the previous trading session, outperforming the S&P 500's gain of 1.16% [1]. - The company is projected to report earnings of $2.09 per share on January 27, 2026, indicating a year-over-year decline of 69.31% [2]. - For the full year, earnings are estimated at $16.3 per share, reflecting a decrease of 41.07%, while revenue is expected to remain flat at $447.7 billion [3]. Analyst Estimates - Recent changes in analyst estimates are crucial for investors, as they often indicate the latest business trends and outlook [3]. - The consensus EPS projection has increased by 0.01% in the past 30 days, and UnitedHealth Group currently holds a Zacks Rank of 3 (Hold) [5]. Valuation Metrics - UnitedHealth Group has a Forward P/E ratio of 19.23, which is higher than the industry average of 15.58, suggesting it is trading at a premium [6]. - The company has a PEG ratio of 2.04, compared to the industry average of 1.04, indicating a higher valuation relative to projected earnings growth [7]. Industry Context - The Medical - HMOs industry, to which UnitedHealth Group belongs, has a Zacks Industry Rank of 215, placing it in the bottom 13% of over 250 industries [7][8].